Effect of Proton Pump Inhibitor Combination with Direct Oral Anticoagulants on the Onset Timing of Central Nervous System Bleeding Disorder - Analysis of the Japanese Adverse Drug Event Reporting System

Le résumé fourni par la source

Proton pump inhibitors (PPIs) have been widely co-administrated to patients with atrial fibrillation who are receiving anticoagulant therapy with a direct oral anticoagulant drug (DOAC), to prevent gastrointestinal bleeding. However, there has been controversy over whether there is an effect of co-administered PPIs on the onset of central nervous system bleeding, which also leads a poor prognosis. We therefore examined the effects of PPIs on the onset timing of adverse drug reactions to DOACs, using the Japanese adverse event reporting database, JADER. After adjusting risk factors for bleeding, the results obtained show that the onset timing of central nervous system bleeding is earlier in rivaroxaban-administered patients co-administered with a PPI as compared to non-PPI-co-administered patients. These results suggest that co-treatment with PPI and rivaroxaban may be a risk factor accelerating the onset of central nervous system bleeding.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.